<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02794948</url>
  </required_header>
  <id_info>
    <org_study_id>YN2014TS06</org_study_id>
    <nct_id>NCT02794948</nct_id>
  </id_info>
  <brief_title>Chinese Medicine(Hu Yang Yang Kun Formula) for Primary Ovarian Insufficiency</brief_title>
  <official_title>Chinese Medicine(Hu Yang Yang Kun Formula) for Primary Ovarian Insufficiency:Randomized, Double-blind, DHEA-controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Guangzhou University of Traditional Chinese Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Guangzhou University of Traditional Chinese Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this research is providing valuable traditional chinese medicine theory and
      formula in treating Primary Ovarian insufficiency.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary ovarian insufficiency is a problem that is to be solved urgently in the field of
      reproductive endocrine. According to the basic theory of traditional Chinese Medicine and
      clinical experience, investigators developed a Chinese medicine formula(Hu yang yang
      kun,Hyyk). This research is designed according to the principle of randomized double blind
      control and evaluated the effectiveness and safety of Hyyk, hope to provide a kind of
      effective medicine in treating primary ovarian insufficiency.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2016</start_date>
  <completion_date type="Actual">December 2017</completion_date>
  <primary_completion_date type="Actual">December 2017</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Anti-Mullerian hormone</measure>
    <time_frame>1year</time_frame>
    <description>Anti-Mullerian hormone (AMH) is a gonadal hormone synthesized by granulose cells of the ovary and Sertoli cells of the testis. Anti-Mullerian hormone is used to facilitate the evaluation of intersex disorders and as a marker in ovarian reserve assessment in the infertility cases.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Follicle stimulating hormone</measure>
    <time_frame>1year</time_frame>
    <description>FSH is a gonadotropin, a glycoprotein polypeptide hormone. FSH is synthesized and secreted by the gonadotropic cells of the anterior pituitary gland,[1] and regulates the development, growth, pubertal maturation, and reproductive processes of the body.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Estrogen</measure>
    <time_frame>1year</time_frame>
    <description>Estrogen is the primary female sex hormone as well as a medication.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Menopause rating scale</measure>
    <time_frame>1year</time_frame>
    <description>The scale was designed and standardized as a self-administered scale to assess symptoms/complaints of aging women under different conditions, to evaluate the severity of symptoms over time, and to measure changes pre- and postmenopause replacement therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Menstrual Cycle</measure>
    <time_frame>1year</time_frame>
    <description>The menstrual cycle is the regular natural change that occurs in the female reproductive system (specifically the uterus and ovaries) that makes pregnancy possible.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">48</enrollment>
  <condition>Primary Ovarian Insufficiency</condition>
  <arm_group>
    <arm_group_label>Chinese Medicine intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Chinese medicine HuYang Yang Kun Formula 1 capsule every time per day for 3 day per month, DHEA(dehydroepiandrosterone) placebo 1 sack every time, twice a day for three months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Western intervention</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>DHEA(dehydroepiandrosterone) 1 sack every time twice a day for three months. Chinese medicine formula granules placebo 1 capsule every time per day for 3 day per month.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Chinese medicine granules (HuYang Yang Kun Formula)</intervention_name>
    <description>Take Chinese medicine granules (HuYang Yang Kun Formula), 1 sack every time,twice a day Take DHEA(dehydroepiandrosterone) placebo,1 capsule every time ,once a day. Treatment for 3 months Both Chinese Medicine formula granules and DHEA placebo were produced by Jiangyin Medical &amp;pharmaceutical limited company in Jiangsu province</description>
    <arm_group_label>Chinese Medicine intervention</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>dehydroepiandrosterone</intervention_name>
    <description>The DHEA( dehydroepiandrosterone)25mg,1 capsule every time once a day. Take Chinese medicine granules placebo , 1 sack every time,twice a day Treatment is 3 months. DHEA were produced by General Nutrition Center(GNC)company in America and The placebo granules of Chinese Medicine were produced by Jiangyin Medical &amp;pharmaceutical limited company in Jiangsu province.</description>
    <arm_group_label>Western intervention</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Aged 18-40

          2. Menstrual cycle change more than 7 days at least 2 times,amenorrhea less than 6
             months.

          3. Sex hormone:bFSH&gt;10u/L;or E2&gt;80pg/ml.

          4. AMH&lt;1ng/ml.

          5. Informed consent and truthfully answer the question.

        Exclusion Criteria:

          1. Dose not meet the inclusion criteria.

          2. Genital tract malformation,congenital germinal aplasia, uterine amenorrhea and so on
             organic disease.

          3. Endocrine diseases such Polycystic ovary syndrome、hyperprolactinemia 、dysfunctional
             uterine bleeding、low gonadotropin menstrual disorders and hyperthyreosis

          4. Autoimmune disease patients:Hashimoto's thyroiditis,SLE,Primary chronic adrenal
             cortical insufficiency,Asthenic bulbar paralysis,Arthritis deformans,Idiopathic
             thrombocytopenic purpura, type I diabetes and so on.

          5. Someone who have the following gynecological operation history:
             oophorocystectomy,ovarian drilling,wedgeshaped oophorectomy,adnexectomy,tubal
             resection,ligation of oviduct,pelvic abscess surgery,uterine arterial embolization.

          6. Someone who have used reproductive toxicity drugs: tripterygium wilfordii,tripterygium
             hypoglaucum hutch,chemotherapeutics and so on.

          7. A family history of ovarian failure.

          8. Have receive hormone therapy in recent 3 months.

          9. Pregnant or lactating women.

         10. with serious heart,liver and kidney disease

         11. With severe psychiatric disorders .

         12. Have participated in other clinical trials in 3 months.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hongyan Yang, professor</last_name>
    <role>Study Chair</role>
    <affiliation>Guangzhou University of Traditional Chinese Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Guangzhou University of Traditional Chinese Medicine</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 19, 2016</study_first_submitted>
  <study_first_submitted_qc>June 8, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 9, 2016</study_first_posted>
  <last_update_submitted>April 9, 2018</last_update_submitted>
  <last_update_submitted_qc>April 9, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 10, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>primary ovarian insufficiency</keyword>
  <keyword>TCM intervention</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Primary Ovarian Insufficiency</mesh_term>
    <mesh_term>Menopause, Premature</mesh_term>
    <mesh_term>Gonadal Dysgenesis</mesh_term>
    <mesh_term>Turner Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dehydroepiandrosterone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

